Concepts (175)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Presbycusis | 8 | 2017 | 12 | 1.540 |
Why?
|
| Temporal Bone | 10 | 2014 | 65 | 1.380 |
Why?
|
| Spiral Ganglion | 9 | 2017 | 26 | 1.060 |
Why?
|
| Cochlea | 7 | 2017 | 52 | 0.780 |
Why?
|
| Otosclerosis | 2 | 2014 | 4 | 0.630 |
Why?
|
| Aging | 3 | 2017 | 770 | 0.630 |
Why?
|
| Receptors, Estrogen | 2 | 2016 | 428 | 0.510 |
Why?
|
| Vestibular Nerve | 1 | 2017 | 33 | 0.500 |
Why?
|
| Goldfish | 1 | 2016 | 6 | 0.490 |
Why?
|
| Vitellogenins | 1 | 2016 | 10 | 0.490 |
Why?
|
| Taxoids | 1 | 2016 | 127 | 0.480 |
Why?
|
| Protein Precursors | 1 | 2016 | 133 | 0.480 |
Why?
|
| Hydroxycholesterols | 1 | 2016 | 6 | 0.470 |
Why?
|
| Selective Estrogen Receptor Modulators | 1 | 2016 | 34 | 0.470 |
Why?
|
| Biological Assay | 1 | 2016 | 82 | 0.460 |
Why?
|
| Cadherins | 1 | 2016 | 184 | 0.450 |
Why?
|
| Stria Vascularis | 2 | 2006 | 5 | 0.450 |
Why?
|
| Estrogen Receptor alpha | 1 | 2016 | 159 | 0.440 |
Why?
|
| Collagen Type I | 2 | 2014 | 75 | 0.430 |
Why?
|
| Keratan Sulfate | 1 | 2014 | 2 | 0.420 |
Why?
|
| Chondroitin Sulfates | 1 | 2014 | 27 | 0.420 |
Why?
|
| Cholesterol | 1 | 2016 | 373 | 0.410 |
Why?
|
| Thyroid Hormones | 1 | 2016 | 358 | 0.400 |
Why?
|
| Cell Membrane | 1 | 2016 | 673 | 0.400 |
Why?
|
| Triple Negative Breast Neoplasms | 1 | 2016 | 212 | 0.400 |
Why?
|
| Cell Movement | 1 | 2016 | 814 | 0.380 |
Why?
|
| Cochlear Nucleus | 1 | 2011 | 6 | 0.360 |
Why?
|
| DNA, Mitochondrial | 5 | 2011 | 211 | 0.350 |
Why?
|
| Liver | 1 | 2016 | 1231 | 0.340 |
Why?
|
| Breast Neoplasms | 2 | 2016 | 3272 | 0.340 |
Why?
|
| Cellular Senescence | 1 | 2011 | 110 | 0.330 |
Why?
|
| Hearing Loss, Sensorineural | 3 | 2004 | 56 | 0.310 |
Why?
|
| Obesity | 2 | 2016 | 1061 | 0.290 |
Why?
|
| Biomarkers, Tumor | 1 | 2016 | 1764 | 0.260 |
Why?
|
| Hair Cells, Vestibular | 1 | 2005 | 20 | 0.230 |
Why?
|
| Antineoplastic Agents | 1 | 2016 | 2373 | 0.230 |
Why?
|
| Audiometry | 4 | 2011 | 12 | 0.220 |
Why?
|
| RNA Interference | 2 | 2016 | 388 | 0.220 |
Why?
|
| Cell Death | 3 | 2016 | 257 | 0.210 |
Why?
|
| Female | 15 | 2017 | 51536 | 0.200 |
Why?
|
| Microdissection | 4 | 2011 | 17 | 0.190 |
Why?
|
| Hair Cells, Auditory | 3 | 2017 | 26 | 0.190 |
Why?
|
| Immunohistochemistry | 3 | 2014 | 1815 | 0.180 |
Why?
|
| Cochlear Nerve | 1 | 2001 | 9 | 0.180 |
Why?
|
| Fluorescent Antibody Technique | 3 | 2011 | 310 | 0.170 |
Why?
|
| Organ of Corti | 3 | 2006 | 10 | 0.160 |
Why?
|
| Humans | 25 | 2017 | 98080 | 0.150 |
Why?
|
| Male | 13 | 2017 | 47076 | 0.140 |
Why?
|
| Collodion | 2 | 2008 | 6 | 0.140 |
Why?
|
| Sequence Deletion | 2 | 2010 | 207 | 0.140 |
Why?
|
| Gene Deletion | 2 | 2011 | 353 | 0.140 |
Why?
|
| Aged | 11 | 2017 | 21758 | 0.130 |
Why?
|
| Reverse Transcriptase Polymerase Chain Reaction | 3 | 2016 | 889 | 0.130 |
Why?
|
| Retrospective Studies | 6 | 2014 | 10973 | 0.130 |
Why?
|
| Aged, 80 and over | 5 | 2014 | 7389 | 0.130 |
Why?
|
| Cell Count | 1 | 2017 | 195 | 0.120 |
Why?
|
| Hearing | 1 | 2017 | 64 | 0.120 |
Why?
|
| Mice, Inbred NOD | 1 | 2016 | 227 | 0.120 |
Why?
|
| Mice, SCID | 1 | 2016 | 278 | 0.120 |
Why?
|
| Lasers | 3 | 2011 | 105 | 0.120 |
Why?
|
| Lead | 1 | 2016 | 35 | 0.120 |
Why?
|
| Estrogen Antagonists | 1 | 2016 | 47 | 0.120 |
Why?
|
| Receptors, Thyroid Hormone | 1 | 2016 | 158 | 0.120 |
Why?
|
| Crime | 1 | 2016 | 38 | 0.120 |
Why?
|
| Microscopy, Confocal | 2 | 2014 | 285 | 0.110 |
Why?
|
| MCF-7 Cells | 1 | 2016 | 123 | 0.110 |
Why?
|
| Tumor Burden | 1 | 2016 | 333 | 0.110 |
Why?
|
| Workflow | 1 | 2016 | 85 | 0.110 |
Why?
|
| Environmental Pollutants | 1 | 2016 | 67 | 0.110 |
Why?
|
| Age of Onset | 1 | 2016 | 367 | 0.110 |
Why?
|
| Chemotherapy, Adjuvant | 1 | 2016 | 525 | 0.110 |
Why?
|
| Neoplasm Invasiveness | 1 | 2016 | 582 | 0.110 |
Why?
|
| Xenograft Model Antitumor Assays | 1 | 2016 | 556 | 0.110 |
Why?
|
| Atrophy | 2 | 2006 | 130 | 0.110 |
Why?
|
| Triiodothyronine | 1 | 2016 | 367 | 0.110 |
Why?
|
| Ligands | 1 | 2016 | 486 | 0.100 |
Why?
|
| Age Factors | 2 | 2011 | 1962 | 0.100 |
Why?
|
| Middle Aged | 9 | 2014 | 29428 | 0.100 |
Why?
|
| Transfection | 1 | 2016 | 883 | 0.100 |
Why?
|
| Up-Regulation | 1 | 2016 | 743 | 0.100 |
Why?
|
| Reference Values | 2 | 2011 | 608 | 0.100 |
Why?
|
| Dose-Response Relationship, Drug | 2 | 2016 | 1950 | 0.100 |
Why?
|
| Neoadjuvant Therapy | 1 | 2016 | 478 | 0.090 |
Why?
|
| Cell Line, Tumor | 2 | 2016 | 2888 | 0.090 |
Why?
|
| Tissue Embedding | 2 | 2011 | 6 | 0.090 |
Why?
|
| Polymerase Chain Reaction | 2 | 2011 | 895 | 0.090 |
Why?
|
| Adult | 9 | 2011 | 29539 | 0.090 |
Why?
|
| Autopsy | 1 | 2011 | 131 | 0.090 |
Why?
|
| Proteoglycans | 1 | 2011 | 76 | 0.080 |
Why?
|
| Skull Neoplasms | 1 | 1991 | 25 | 0.080 |
Why?
|
| Cytochrome-c Oxidase Deficiency | 1 | 2010 | 3 | 0.080 |
Why?
|
| Cell Separation | 1 | 2011 | 200 | 0.080 |
Why?
|
| Receptor Protein-Tyrosine Kinases | 1 | 2011 | 159 | 0.080 |
Why?
|
| Gene Expression Regulation, Neoplastic | 1 | 2016 | 1394 | 0.080 |
Why?
|
| RNA, Messenger | 1 | 2016 | 2063 | 0.080 |
Why?
|
| Child | 5 | 2016 | 7681 | 0.080 |
Why?
|
| Case-Control Studies | 2 | 2011 | 1995 | 0.080 |
Why?
|
| Stapes Surgery | 1 | 1989 | 6 | 0.070 |
Why?
|
| Time Factors | 2 | 2016 | 5567 | 0.070 |
Why?
|
| Cadaver | 2 | 2011 | 202 | 0.070 |
Why?
|
| Chromosome Deletion | 1 | 2009 | 214 | 0.070 |
Why?
|
| Esophageal Neoplasms | 1 | 2011 | 353 | 0.070 |
Why?
|
| Tissue Adhesives | 1 | 2008 | 22 | 0.070 |
Why?
|
| Proteomics | 1 | 2010 | 279 | 0.070 |
Why?
|
| In Situ Nick-End Labeling | 1 | 2008 | 122 | 0.070 |
Why?
|
| Stomach Neoplasms | 1 | 2011 | 319 | 0.070 |
Why?
|
| Hearing Loss | 1 | 2008 | 68 | 0.070 |
Why?
|
| Severity of Illness Index | 2 | 2011 | 2013 | 0.060 |
Why?
|
| Bone and Bones | 1 | 2008 | 270 | 0.060 |
Why?
|
| Animals | 2 | 2016 | 28894 | 0.060 |
Why?
|
| Sensitivity and Specificity | 2 | 2011 | 1945 | 0.060 |
Why?
|
| Linear Models | 1 | 2006 | 424 | 0.060 |
Why?
|
| Biopsy, Needle | 1 | 2005 | 226 | 0.060 |
Why?
|
| Child, Preschool | 3 | 2016 | 4001 | 0.060 |
Why?
|
| Adolescent | 4 | 2011 | 10080 | 0.050 |
Why?
|
| Risk Factors | 1 | 2016 | 6233 | 0.050 |
Why?
|
| Adenocarcinoma | 1 | 2011 | 1211 | 0.050 |
Why?
|
| Citalopram | 1 | 2003 | 22 | 0.050 |
Why?
|
| Neurons | 1 | 2011 | 1619 | 0.050 |
Why?
|
| Bulimia | 1 | 2003 | 147 | 0.050 |
Why?
|
| Tobramycin | 1 | 2001 | 5 | 0.040 |
Why?
|
| Gentamicins | 1 | 2001 | 20 | 0.040 |
Why?
|
| Apoptosis | 1 | 2008 | 1752 | 0.040 |
Why?
|
| Deafness | 1 | 2001 | 50 | 0.040 |
Why?
|
| Cochlear Implantation | 1 | 2001 | 37 | 0.040 |
Why?
|
| Young Adult | 1 | 2011 | 7507 | 0.040 |
Why?
|
| Electron Transport Complex IV | 2 | 2008 | 48 | 0.030 |
Why?
|
| Feasibility Studies | 2 | 2011 | 801 | 0.030 |
Why?
|
| Missouri | 1 | 2016 | 26 | 0.030 |
Why?
|
| Cities | 1 | 2016 | 62 | 0.030 |
Why?
|
| Environmental Exposure | 1 | 2016 | 405 | 0.020 |
Why?
|
| Chondroitin Sulfate Proteoglycans | 1 | 2011 | 11 | 0.020 |
Why?
|
| Indicators and Reagents | 1 | 2011 | 68 | 0.020 |
Why?
|
| Receptors, Growth Factor | 1 | 2011 | 52 | 0.020 |
Why?
|
| Petrous Bone | 1 | 1991 | 9 | 0.020 |
Why?
|
| Hepatocyte Growth Factor | 1 | 2011 | 86 | 0.020 |
Why?
|
| STAT3 Transcription Factor | 1 | 2011 | 91 | 0.020 |
Why?
|
| Drug Administration Schedule | 2 | 2003 | 839 | 0.020 |
Why?
|
| Ear, Middle | 1 | 1991 | 28 | 0.020 |
Why?
|
| Fixatives | 1 | 2010 | 13 | 0.020 |
Why?
|
| Tissue Fixation | 1 | 2010 | 39 | 0.020 |
Why?
|
| Gene Dosage | 1 | 2011 | 216 | 0.020 |
Why?
|
| Staining and Labeling | 1 | 2011 | 161 | 0.020 |
Why?
|
| Formaldehyde | 1 | 2010 | 52 | 0.020 |
Why?
|
| Reference Standards | 1 | 2011 | 146 | 0.020 |
Why?
|
| In Situ Hybridization, Fluorescence | 1 | 2011 | 370 | 0.020 |
Why?
|
| Microscopy | 1 | 2010 | 92 | 0.020 |
Why?
|
| Infant, Newborn | 1 | 2016 | 2529 | 0.020 |
Why?
|
| Proto-Oncogene Proteins c-met | 1 | 2011 | 199 | 0.020 |
Why?
|
| Auditory Threshold | 1 | 2009 | 15 | 0.020 |
Why?
|
| RNA, Small Interfering | 1 | 2011 | 564 | 0.020 |
Why?
|
| Indoles | 1 | 2011 | 334 | 0.020 |
Why?
|
| Piperazines | 1 | 2011 | 306 | 0.020 |
Why?
|
| Data Interpretation, Statistical | 1 | 2011 | 313 | 0.020 |
Why?
|
| Infant | 1 | 2016 | 3328 | 0.020 |
Why?
|
| Sulfonamides | 1 | 2011 | 351 | 0.020 |
Why?
|
| DNA Primers | 1 | 2008 | 530 | 0.020 |
Why?
|
| Proto-Oncogene Proteins | 1 | 2011 | 682 | 0.020 |
Why?
|
| Protein Kinase Inhibitors | 1 | 2011 | 640 | 0.020 |
Why?
|
| Base Sequence | 1 | 2008 | 2222 | 0.010 |
Why?
|
| Molecular Sequence Data | 1 | 2008 | 2896 | 0.010 |
Why?
|
| Titrimetry | 1 | 2003 | 14 | 0.010 |
Why?
|
| Prognosis | 1 | 2011 | 4116 | 0.010 |
Why?
|
| Depressive Disorder | 1 | 2003 | 231 | 0.010 |
Why?
|
| Reproducibility of Results | 1 | 2008 | 2784 | 0.010 |
Why?
|
| Audiometry, Pure-Tone | 1 | 2001 | 29 | 0.010 |
Why?
|
| Drug Interactions | 1 | 2001 | 239 | 0.010 |
Why?
|
| Models, Biological | 1 | 2008 | 1807 | 0.010 |
Why?
|
| Signal Transduction | 1 | 2011 | 3620 | 0.010 |
Why?
|
| Drug Therapy, Combination | 1 | 2001 | 764 | 0.010 |
Why?
|
| Body Mass Index | 1 | 2003 | 850 | 0.010 |
Why?
|
| Mutation | 1 | 2011 | 4392 | 0.010 |
Why?
|
| Double-Blind Method | 1 | 2003 | 1782 | 0.010 |
Why?
|
| Surveys and Questionnaires | 1 | 2003 | 3022 | 0.010 |
Why?
|
| Antineoplastic Combined Chemotherapy Protocols | 1 | 2001 | 2658 | 0.010 |
Why?
|